1. |
Karsenty G. The complexities of skeletal biology. Nature, 2003, 423(6937): 316-318.
|
2. |
Zeng XZ, He LG, Wang S, et al. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression. Acta Pharmacol Sin, 2016, 37(2): 255-263.
|
3. |
Qu X, Zhai Z, Liu X, et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun, 2014, 443(2): 658-665.
|
4. |
Zhao N, Tsuda H, Murofushi T, et al. Chaetocin inhibits RANKL-induced osteoclast differentiation through reduction of Blimp1 in Raw264.7 cells. Life Sci, 2015, 143: 1-7.
|
5. |
Choe JY, Kim SK. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages. Int J Mol Med, 2017, 39(3): 539-548.
|
6. |
Ye S, Fowler TW, Pavlos NJ, et al. LIS1 regulates osteoclast formation and function through its interactions with dynein/dynactin and Plekhm1. PLoS One, 2011, 6(11): e27285.
|
7. |
Strålberg F, Kassem A, Kasprzyowski F, et al. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors. J Leukoc Biol, 2017, 101(5): 1233-1243.
|
8. |
Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A, 1998, 95(7): 3597-3602.
|
9. |
Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res, 2013, 92(10): 860-867.
|
10. |
Chung YH, Chang EJ, Kim SJ, et al. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. J Periodontal Res, 2006, 41(4): 288-296.
|
11. |
Islam S, Hassan F, Tumurkhuu G, et al. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem Biophys Res Commun, 2007, 360(2): 346-351.
|
12. |
Zhai ZJ, Li HW, Liu GW, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol, 2014, 171(3): 663-675.
|
13. |
Qin A, Cheng TS, Lin Z, et al. Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One, 2012, 7(4): e34132.
|
14. |
Zou W, Izawa T, Zhu T, et al. Talin1 and Rap1 are critical for osteoclast function. Mol Cell Biol, 2013, 33(4): 830-844.
|
15. |
Ilvesaro J, Väänänen K,Tuukkanen J. Bone-resorbing osteoclasts contain gap-junctional connexin-43. J Bone Miner Res, 2000, 15(5): 919-926.
|
16. |
Hobolt-Pedersen AS, Delaissé JM, Soe L. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif Tissue Int, 2014, 95(1): 73-82.
|
17. |
Kang JH, Sim JS, Zheng T, et al. F4/80 inhibits osteoclast differentiation via downregulation of nuclear factor of activated T cells, cytoplasmic 1. Arch Pharm Res, 2017, 40(4): 492-499.
|
18. |
Lee K, Chung YH, Ahn H, et al. Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation. Int J Biol Sci, 2016, 12(2): 235-245.
|
19. |
Kylmäoja E, Kokkonen H, Kauppinen K, et al. Osteoclastogenesis is influenced by modulation of gap junctional communication with antiarrhythmic peptides. Calcif Tissue Int, 2013, 92(3): 270-281.
|
20. |
Shi C, Zhang H, Louie K, et al. BMP signaling mediated by BMPR1A in osteoclasts negatively regulates osteoblast mineralization through suppression of Cx43. J Cell Biochem, 2017, 118(3): 605-614.
|
21. |
Schilling AF, Filke S, Lange T, et al. Gap junctional communication in human osteoclasts in vitro and in vivo. J Cell Mol Med, 2008, 12(6A): 2497-2504.
|
22. |
Xing Q, de Vos P, Faas MM, et al. LPS promotes pre-osteoclast activity by up-regulating CXCR4 via TLR-4. J Dent Res, 2011, 90(2): 157-162.
|